
CNAT
Healthcare · Biotechnology · $18.4M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 1, 2020 | Time not confirmed | — | -0.10 | — |
| Mar 12, 2020 | Time not confirmed | — | -0.08 | — |
| Nov 6, 2019 | Time not confirmed | -0.12 | -0.10 | +16.7% |
| Aug 7, 2019 | Time not confirmed | -0.12 | -0.02 | +83.3% |
| May 3, 2019 | Time not confirmed | -0.12 | -0.14 | -16.7% |
| Mar 11, 2019 | Time not confirmed | -0.14 | -0.13 | +7.1% |
| Nov 2, 2018 | Time not confirmed | -0.15 | -0.15 | -1.3% |
| Aug 2, 2018 | Time not confirmed | -0.20 | -0.15 | +25.4% |
| May 3, 2018 | Time not confirmed | -0.17 | -0.17 | +1.8% |
| Mar 8, 2018 | Time not confirmed | -0.17 | -0.15 | +14.6% |
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for…